STML
Stemline Therapeutics, Inc.
STML
STML
Delisted
STML was delisted on the 9th of June, 2020.
98 hedge funds and large institutions have $436M invested in Stemline Therapeutics, Inc. in 2019 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 23 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
7% more funds holding
Funds holding: 92 → 98 (+6)
87% less call options, than puts
Call options by funds: $365K | Put options by funds: $2.78M
Holders
98
Holding in Top 10
4
Calls
$365K
Puts
$2.78M
Top Buyers
| 1 | +$38.6M | |
| 2 | +$35.9M | |
| 3 | +$25.7M | |
| 4 |
Goldman Sachs
New York
|
+$17M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.5M |
Top Sellers
| 1 | -$11M | |
| 2 | -$9.26M | |
| 3 | -$6.82M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.63M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$5.17M |